Holen Sie sich die Stockscreener-App
49.91
1.09%
-0.55
Handel nachbörslich:
49.90
-0.010
-0.02%
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Supernus Pharmaceuticals Stock Review: Valuation & Business Quality ConcernsNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Supernus at Barclays Conference: Strategic Growth and Future Prospects By Investing.com - Investing.com Canada
To promote Zurzuvae, Biogen and Supernus are Turning Tides against postpartum depression - Medical Marketing and Media
Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by Jefferies Financial Group Inc. - MarketBeat
Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc. - MarketBeat
Insider Selling Alert: Georges Gemayel Sells Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus
Insider Selling: Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells 10,000 Shares of Stock - MarketBeat
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Recap Report: Is Supernus Pharmaceuticals Inc being accumulated by smart moneyTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Buy" at Wall Street Zen - MarketBeat
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update - Sahm
Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
GW&K Investment Management LLC Sells 184,268 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus (NASDAQ: SUPN) CFO receives performance share unit grant - Stock Titan
Supernus Pharmaceuticals (SUPN) CEO awarded 38,640 performance units - Stock Titan
Supernus Pharmaceuticals (SUPN) SVP gets 3,750 performance share units - Stock Titan
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One-Year Surge? - simplywall.st
Supernus Pharmaceuticals (SUPN) Stock Analysis: A 14.66% Upside and Strong Buy Ratings Shape Investor Outlook - DirectorsTalk Interviews
Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally? - Yahoo Finance
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Supernus at TD Cowen Conference: Strategic Diversification Unveiled By Investing.com - Investing.com South Africa
Supernus at TD Cowen Conference: Strategic Diversification Unveiled - Investing.com
Supernus Pharmaceuticals (SUPN) Releases Q4 2025 Earnings: Revenue Up, Operating and Net Losses - Quiver Quantitative
Supernus Pharmaceuticals 2025 10-K: $718.95M Revenue, $(0.68) EPS - TradingView
Sage acquisition and ZURZUVAE strategy reshape Supernus (NASDAQ: SUPN) - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc. - MarketBeat
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
A Look At Supernus Pharmaceuticals (SUPN) Valuation After Record Revenues And 2026 Guidance - simplywall.st
Supernus (SUPN) SVP reports RSU vesting and tax-withholding share disposition - Stock Titan
Supernus (NASDAQ: SUPN) CFO reports RSU vesting and tax share withholding - Stock Titan
SUPERNUS (NASDAQ: SUPN) executive logs RSU grant and tax share withholding - Stock Titan
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - simplywall.st
Supernus Pharmaceuticals stock hits 52-week high at $57.76 By Investing.com - Investing.com Australia
Supernus (NASDAQ: SUPN) CFO logs RSU vesting, stock awards and tax withholdings - Stock Titan
Director in Supernus (NASDAQ: SUPN) gets 4,475-share stock award - Stock Titan
[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Supernus (SUPN) director Carrolee Barlow granted 4,475 common shares - Stock Titan
Supernus (SUPN) SVP gets stock awards, shares withheld for taxes - Stock Titan
Supernus (SUPN) CMO awarded stock as shares withheld for taxes - Stock Titan
TD Cowen raises Supernus Pharmaceuticals stock price target on Onapgo relaunch - Investing.com Nigeria
Supernus Pharmaceuticals stock hits 52-week high at $57.76 - Investing.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month HighTime to Buy? - MarketBeat
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains - Investing.com Nigeria
Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cantor Fitzgerald reiterates Supernus stock Overweight on supply gains By Investing.com - Investing.com UK
Supernus FY25 Total Revenues Up 9%; Guides 17-21% Growth For FY26 - RTTNews
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q4 2025 Earnings Conference - 富途牛牛
Supernus Pharmaceuticals Swings to Q4 Loss, Revenue Rises - marketscreener.com
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook Highlights 21% Potential Upside - DirectorsTalk Interviews
Supernus Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highli - GuruFocus
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):